Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Circassia has released Phase II clinical trial results demonstrating that the patients who has been given four doses of ToleroMune cat allergy vaccine for a period of 12-week have maintained a reduction in symptoms one year later.
Subscribe to our email newsletter
Earlier, the study was initiated as a randomized double-blind Phase II trial in 202 cat allergy patients, in which those who received four doses of Circassia’s T-cell vaccine over 12 weeks had an improvement in their symptoms than those on placebo.
The company said after receiving the vaccine since one year, the treated group’s tolerance to cat allergens was maintained, and had continued to improve substantially following the completion of the treatment, despite the patients receiving no booster doses.
The trial results suggested the patients had experienced a 94% improvement in their total rhinitis symptoms compared with placebo.
By the end of the 12-month study, the ToleroMune T-cell vaccine had reduced the same patients’ symptoms by 133% more than placebo.
Circassia CEO Steve Harris said these results, achieved with their commercial room-temperature-stable formulation, clearly show that Circassia’s T-cell vaccines offer the prospect of major clinical and manufacturing benefits over traditional immunotherapies.
"We intend to capitalize on these impressive results as quickly as possible, and having recently completed one of the largest private fundraisings in the history of European biotechnology, plan to advance our cat allergy treatment into phase III testing in 2012," Harris said.